Incyte (INCY) and Genesis Therapeutics announced that the companies have entered into a strategic collaboration focused on the research, discovery and development of novel small molecule medicines ...

WILMINGTON, Del. & BURLINGAME, Calif., February 20, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic ...

Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte ...

Incyte will partner with Genesis Therapeutics to research, discover, and develop small molecule treatments through a collaboration that could generate at least up to $620 million for Genesis ...

Genesis is pioneering generative and predictive artificial intelligence (AI) technologies to help create therapeutics for challenging targets. Utilizing Genesis’ proprietary AI platform ...

Under the financial terms of the deal, the Wilmington-based biotechnology company will make an upfront payment of $30 million to Genesis Therapeutics, which is eligible to receive up to $885 ...

Incyte (INCY) and Genesis Therapeutics announced that the companies have entered into a strategic collaboration focused on the research, ...

WILMINGTON, Del. & BURLINGAME, Calif., February 20, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic ...

Incyte is sticking to its strategy this year of finding “early-stage, exotic stuff”—paying Genesis Therapeutics $30 million upfront to use the biotech’s artificial intelligence platform to ...